author-photo

Howard S. Hochster

New York University

149

Papers

8266

Citations

Citation Trend

Filter By

Papers (110) Sort By

Journal Conference Others

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

2018 Oncologist
Show All
- Source
- Cite
- Save
Citations (30)
Genomic mutations and histopathologic biomarkers in Y 90 radioembolization for chemorefractory colorectal liver metastases

2018 Oncotarget
Show All
- Source
- Cite
- Save
Citations (3)
Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation

2018 Journal of gastrointestinal oncology
Show All
- Source
- Cite
- Save
Citations (2)
Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (25)
A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)